

The STATus Report

Seabreeze STAT Asthma (CBP-201-206) Update

Volume 1 – Issue 1

November 2025 Topics:

- ❖ Enrollment Update
- ❖ Questions & Answers
- ❖ Data Management Updates

Message from Connect Leadership

Thank you to all the sites who attended our Investigator Meetings in San Diego and Amsterdam in September. We hope you found them informative and had a little fun!

This is the inaugural issue of *The Seabreeze STATus Report* monthly newsletter in which we share the status of your Seabreeze STAT Asthma study and provide answers to common study questions. We also want to hear from you – so let us know what you want to know each month.

The Seabreeze STAT program has reached several significant milestones in the past 2 months. Clinical study sites have been activated in the US, Georgia, Australia, and the UK and study participants have already been screened, randomized and dosed in the US and Georgia. We look forward to initiating the program in the UK, Serbia and Argentina in the coming weeks.


Thank you for working with us to improve the care and outcomes for asthma patients experiencing acute attacks!



Kimberly J. Manhard
EVP, Chief Development Officer

Enrollment Update

Goal = 160 Patients



First Sites to Randomize

- ❖ Site 1406 – Dr. Shvelidze
- ❖ Site 1402 – Dr. Peikrishvili
- ❖ Site 1401 – Dr. Toidze
- ❖ Site 1403 – Dr. Gonjilashvili
- ❖ Site 1103 – Dr. Llerena

In Focus: Clinical Brief

Question & Answers

Q: When should I order additional lab kits?

A: Ordering as soon as possible when expecting enrollments helps avoid delays as LabConnect is experiencing high order volume and lab kit re-supply may take up to several weeks

Q: How do I calculate pack-years for vaping or marijuana use?

A: Guidance for calculating the pack-years is available in the CRF Completion Guidelines and Section 11.1.2 of Protocol Version 3.1


Q: Can maintenance bronchodilators be reimbursed for patients during study participation?

A: Yes, please include them as a budget line item so your Site may get reimbursed

Q: If there is no historical evidence of airflow limitation at Visit 1a do we need to perform spirometry to demonstrate airflow reversibility?

A: Yes, you will need to provide evidence of current airflow limitation at visit 1a by performing pre- and post-bronchodilator spirometry and demonstrating airflow reversibility as outlined in Inclusion Criterion #7

Site Activations (as of 11/13/25)



Data Management Reminders/Updates

- ❖ Informed Consent version in Medrio:
We are aware most consents do not have a version number. This field will be updated to a date in the future; however, please select "Version 1" until the appropriate update has been made.
- ❖ Protocol Version in Medrio:
We are aware Medrio does not allow for a decimal in the protocol version field. If your site is operating under a protocol version with a decimal, please round to the closest Version number.
- ❖ Sites should update their Source Documents to reflect latest CRF update on Health Care Resource Utilization questions.
- ❖ Sites should ensure data entry in EDC is completed as soon as possible
- ❖ Sites can utilize prior Medrio certification to complete training requirements for the Seabreeze STAT Asthma trial

Seabreeze STAT Asthma Resources

Check out seabreezestatasthma.com for:

- ❖ Investigator Meeting recordings/slides with interactive Trivia questions
- ❖ Safety Reporting Forms and Medical Monitor Maps
- ❖ Latest Protocol Updates





Investigator Meeting, San Diego

Connect Biopharma would like to thank the entire Seabreeze STAT Asthma Team for their participation in our recent Investigator Meetings.



Investigator Meeting, Amsterdam